Psoriasis: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• IL-17 12
• IL-23 6
• STAT3 0
• TNF 5
• JAK 1
• GLP-1 5
• TYK2 1
• PI3K 0
• NLRP3 0
• IL-6 0
• IL-1 0
• AKT 0
• MAPK 0
• PDE4 1
• NRF2 0
• PD-1 0
• PPAR 0
• STING 0
• mTOR 0
• TLR4 0
• AMPK 0
• ERK 0
• GIP 1
• VEGF 0
• MMP-9 0
• PD-L1 0
• COX-2 0
• HIF-1 0
• IL-4 0
• SIRT1 0
• TP53 0
• APOE 0
• CGRP 0
• IL-13 0
• KEAP1 0
• LAG-3 0
• PCSK9 0
• PKM2 0
• SGLT2 0
• TSLP 0
• AR 0
• BCL-2 0
• BDNF 0
• BRD4 0
• CD123 0
• CD19 0
• CD40 0
• CSF1R 0
• CTLA-4 0
• CTNNB1 0
• CXCR4 0
• EGFR 0
• EZH2 0
• FTO 0
• G6PD 0
• GPRC5D 0
• HMGB1 0
• HSP90 0
• IDH 0
• JNK 0

24 of 1,932 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Synergistic Nano-Therapeutic Approach for Psoriasis: Targeting TNF-α and IL-17 Pathways via Transdermal Delivery (SKINNOVATE)

  Academisch Ziekenhuis Groningen· Groningen, Netherlands· EU contribution €232,916· until Oct 2027

• European Commission (Horizon Europe) · HORIZON-ERC

  Unmasking Non-Genetic Determinants Instructing Tumor Initiation (IGNITE)

  Fundacio Institut de Recerca Biomedica (Irb Barcelona)· Barcelona, Spain· EU contribution €1,995,000· until Sept 2030

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Positive allosteric modulators of the PD-1•PD-L1 interaction as a new mode of therapeutic intervention for autoimmune diseases: preclinical proof of concept in humanized mice (PAMinMICE)

  Vib Vzw· Zwijnaarde - Gent, Belgium· EU contribution €150,000· until Feb 2027

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Dissolving microneedle array patch-based psoriatic immunotherapy using nanoparticles (MAPiT)

  Stockholms Universitet· Stockholm, Sweden· EU contribution €222,728· until Feb 2027

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Overcoming limits for pre-clinical small volume liquid delivery into skin and inflammation quantification (Lab-In-Skin)

  Universiteit Twente· Enschede, Netherlands· EU contribution €150,000· until Dec 2026

  The disease is named only in the funder's project summary, not in the title.

5 of 9 running projects, newest first. Listed amounts together: €31.3m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Suspended

  Evaluation of Safety and Efficacy of IRX4204 in Mild to Moderate Plaque Psoriasis

  NCT06723171· Io Therapeutics· Updated 12 Nov 2026

  “Sponsor request for study hold, funding issues”Registry text, quoted unchanged. Source

• Suspended

  A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

  NCT04031469· ProgenaBiome· Updated 21 Sept 2026

  “Administrative”Registry text, quoted unchanged. Source

• Terminated

  A Phase 2 Study of ZL-1102 in Patients With Chronic Plaque Psoriasis

  NCT06380907· Zai Lab (Hong Kong), Ltd.· Updated 10 Aug 2026

  “Sponsor decision”Registry text, quoted unchanged. Source

• Terminated

  A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis

  NCT07314060· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Updated 3 Aug 2026

  “Due to the company's strategic adjustment in product portfolio, this study has been voluntarily terminated.”Registry text, quoted unchanged. Source

• Terminated

  A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis

  NCT07449234· Janssen-Cilag Ltd.· Updated 27 Jul 2026

  “Study terminated due to insufficient enrollment.”Registry text, quoted unchanged. Source

• Terminated

  Local Methotrexate Injections for the Treatment of Nail Psoriasis

  NCT06578728· Weill Medical College of Cornell University· Updated 17 Jun 2026

  “The study was terminated due to slow accrual.”Registry text, quoted unchanged. Source

• Terminated

  A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis

  NCT06042920· Bristol-Myers Squibb· Updated 17 Apr 2026

  “Business objectives have changed”Registry text, quoted unchanged. Source

• Terminated

  Evaluation of Allocetra by Intra-articular Injection for the Treatment of Psoriatic Arthritis

  NCT06522035· Enlivex Therapeutics Ltd.· Updated 13 Apr 2026

  “reprioritization”Registry text, quoted unchanged. Source

• Withdrawn

  Spesolimab Post-marketing Surveillance in Korean Patients With Flares With Generalized Pustular Psoriasis

  NCT06886009· Boehringer Ingelheim· Updated 31 Mar 2026

  “Sponsor decision”Registry text, quoted unchanged. Source

• Withdrawn

  Pregnancy and Medically Assisted Conception in Rare Diseases

  NCT02450396· Assistance Publique - Hôpitaux de Paris· Updated 27 Mar 2026

  “Abandonment of the study project”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study to Assess Targeted Therapies for Treatment of Adults With Moderate to Severe Psoriasis

  NCT07933536· AbbVie· Source

• Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis

  NCT07286058· Takeda· Source

• Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

  NCT03816345· National Cancer Institute (NCI)· Source

• A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

  NCT06671483· Takeda· Source

• An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored Secukinumab study and are judged by the investigator to benefit from continued Secukinumab treatment

  NCT04638647· Novartis Pharma AG· Source

• Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis

  NCT06865105· AbbVie· Source

• A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis

  NCT07801495· Novartis Pharmaceuticals· Source

• Extension Study of Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis (CDDY391A12201-extension)

  NCT07923773· Novartis Pharmaceuticals· Source

• Impact of Glucagon-like Peptide-1 (GLP-1) Analogs on Disease Outcomes in Psoriatic Arthritis: A Pragmatic Randomized Controlled Trial

  NCT07111494· Medical College of Wisconsin· Source

• A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis

  NCT06095115· Janssen Research & Development, LLC· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 28
• Mendelian Randomization Analysis 38
• CRISPR-Cas Systems 4
• Gene Expression Profiling 66
• Sequence Analysis, RNA 6
• Exome Sequencing 5
• Proteomics 24
• Metabolomics 13
• Flow Cytometry 11
• Immunohistochemistry 24
• Xenograft Model Antitumor Assays 1
• Positron-Emission Tomography 1
• Magnetic Resonance Imaging 23
• Machine Learning 27
• Deep Learning 4
• Cohort Studies 63
• Genome-Wide Association Study 38

• FDA-approved dimethyl fumarate targets thioredoxin reductase to induce apoptosis in triple-negative breast cancer.

  Free Radic Biol Med, Aug 2026

See which targets of this disease your abstract mentions, and go to the people working on them.